Trial Profile
A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-427
- Sponsors Merck Sharp & Dohme
- 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell.
- 29 Aug 2022 This trial has been completed in Poland (Date of the global end of the trial :01-Apr-2022), according to European Clinical Trials Database record.
- 22 Apr 2022 This trial has been completed in Germany (Global end date: 1 Apr 2022).